arrow
D

Daniel Pink

universität greifswald
H指数:33
被引数:8,564

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Variations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres

德语区肉瘤中心在腹膜后肉瘤的手术策略和治疗分配方面的差异

EJSO
IF2.9
2026-08-010
PRE
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

作者更正:一线改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗或FLOT联合纳武利尤单抗治疗晚期胃食管腺癌:一项II期多队列IKF-AIO-MOONLIGHT试验

2026-04-170
OAAI
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial

一项随机临床试验比较曲贝替定联合区域性高温疗法与曲贝替定在晚期软组织肉瘤患者中的疗效:HyperTET,一项德国多学科肉瘤组试验

2026-04-090
OAAI
Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

从一线到三线治疗的胰腺癌患者治疗格局及生活质量数据,来自德国PARAGON(胰腺癌结局、生活质量及转化研究平台)登记研究(IKF-PARAGON研究)。

2025-12-010
OAAI
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition

去分化脂肪肉瘤的长期疾病控制: trabectedin引发PD-1抑制的病例报告

2025-01-160
OAAI
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
2024-10-011
PRE
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial

改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗对比FLOT联合纳武利尤单抗治疗既往未接受治疗的胃或胃食管结合部腺癌晚期或转移性患者的最终结果:IKF-AIO-Moonlight试验

2024-09-012
PRE
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group e The IKF-057/ PRESTO trial

以度伐利尤单抗为基础的免疫疗法联合化疗放疗作为早期、cT1和cT2N0食管腺癌根治性治疗的器官保留:FLOT-AIO胃癌研究组开展的IKF-057/PRESTO试验一项前瞻性、多中心研究

2024-09-010
PRE
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC) a multicentre, open-label, randomised, phase 2 trial
2024-08-013
OAAI
Regional hyperthermia for soft tissue sarcoma - a survey on current practice, controversies and consensus among 12 European centers

软组织肉瘤的区域热疗-对12个欧洲中心的当前实践,争议和共识的调查

2024-04-230
OA
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy
2024-03-066
OA
Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas
2023-10-012
PRE
Health related Quality of Life over time in German sarcoma patients. An analysis of associated factors - results of the PROSa study
2023-08-295
OAAI
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review

热疗治疗高危软组织肉瘤的系统评价

2023-07-195
OA
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

Ramucirumab加伊立替康/亚叶酸/5-FU与ramucirumab加紫杉醇治疗晚期或转移性胃或胃食管交界处腺癌的患者,这些患者先前的姑息化疗失败: II/III期RAMIRIS研究 (AIO-STO-0415)

2023-06-194
OAAI
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
2023-03-2313
PRE